Blue Jet Healthcare Limited

NSE: BLUEJET · Healthcare

₹553.80-3.91%06 Nov 2026

Ask the data

Instant answers about Blue Jet Healthcare Limited — computed from its filings, no language model

Market cap₹10,482 cr

Current price₹553.80

High / Low₹674 / ₹327

P/E36.7

P/B4.56

Book value₹121.4

ROE12.4%

ROCE16.8%

Debt / equity0.00

Dividend yield0.20%

EPS (TTM)₹15.07

Face value₹2

Price & valuation

split & bonus adjusted · pick a metric and range

Annual performance

annual · ₹ crore · line = operating margin

	FY24	FY25	FY26
Revenue	712	1,030	947
EBITDA	229	378	294
Operating margin	32.2%	36.7%	31.0%
Interest	0	0	6
Depreciation	28	18	24
Profit before tax	220	406	333
Tax	56	101	85
Net profit	164	305	248
EPS ₹	9.44	17.59	14.29
Operating cash flow	241	46	334
Capex	173	80	0
Dividend paid	0	17	21
Total assets	1,059	1,418	1,641
Equity	845	1,133	1,360

Quarterly performance

last 13 quarters · ₹ crore

showing latest 8 of 13 periods

	SEP '23	DEC '23	MAR '24	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
Revenue	181	167	184	163	208	318	340	355	165	192	235	293	376
Operating profit	63	55	53	44	69	124	140	121	55	47	71	98	119
Operating margin	34.5%	32.7%	28.9%	27.2%	33.4%	39.0%	41.1%	34.1%	33.2%	24.4%	30.4%	33.5%	31.6%
Other income	8	7	9	9	12	13	12	8	24	13	23	15	26
Interest	0	0	0	0	0	0	0	1	5	0	1	1	1
Depreciation	6	8	8	3	5	5	5	6	6	6	6	7	7
Profit before tax	64	44	54	49	77	132	147	123	69	54	87	106	137
Tax	16	12	14	12	19	34	37	32	17	14	23	28	35
Net profit	48	32	39	38	58	99	110	91	52	40	64	78	103
EPS ₹	2.76	1.85	2.29	2.18	3.36	5.71	6.35	5.26	3.01	2.32	3.71	4.51	5.46
Revenue YoY	—	—	—	—	14.8%	90.9%	85.1%	117.8%	-20.5%	-39.6%	-31.1%	-17.4%	127.1%
Profit YoY	—	—	—	—	21.9%	208.3%	178.8%	141.3%	-10.6%	-59.4%	-41.6%	-14.2%	96.6%

Returns & margins

trailing-twelve-month, per quarter

showing latest 8 of 10 periods

	JUN '24	SEP '24	DEC '24	MAR '25	JUN '25	SEP '25	DEC '25	MAR '26	JUN '26	SEP '26
ROE	18.6%	18.2%	25.4%	26.9%	31.6%	28.1%	23.4%	18.2%	17.3%	12.4%
ROCE	25.1%	24.3%	33.9%	35.8%	42.4%	38.0%	31.7%	24.9%	23.7%	16.8%
Net margin	22.6%	23.2%	26.9%	29.6%	29.3%	29.9%	27.9%	26.2%	26.5%	26.0%
EBITDA margin	30.9%	30.7%	33.3%	36.7%	37.2%	37.3%	34.5%	31.0%	30.6%	30.6%
Debt / equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest coverage	1512.79	1869.67	3131.30	4061.90	631.89	88.76	69.99	54.29	51.82	174.09
Asset turnover	0.66	0.61	0.74	0.73	0.86	0.77	0.69	0.58	0.54	0.42

Balance sheet

equity vs borrowings over time · ₹ crore

showing latest 6 of 7 periods

	SEP '23	MAR '24	SEP '24	MAR '25	SEP '25	MAR '26	SEP '26
Share capital	35	35	35	35	35	35	38
Other equity / reserves	739	811	889	1,098	1,221	1,325	2,261
Total equity	774	845	924	1,133	1,256	1,360	2,299
Borrowings	0	0	0	0	0	0	0
Current liabilities	183	206	246	256	241	227	233
Non-current liabilities	7	8	11	29	31	54	53
Total assets	964	1,059	1,181	1,418	1,527	1,641	2,584
Property, plant & equipment	161	172	268	260	302	314	326
Capital work-in-progress	64	147	85	89	159	301	358
Investments	211	250	293	187	210	252	675
Inventories	148	130	178	264	197	187	251
Receivables	206	177	212	350	312	339	445
Cash & equivalents	55	41	30	33	67	61	77

Cash flow

annual · ₹ crore · line = free cash flow

	FY24	FY25	FY26
Cash from operations	241	46	334
Cash from investing	-264	-35	-276
Cash from financing	-2	-19	-31
Capex	173	80	0
Free cash flow	68	-34	334
Dividends paid	0	17	21

Where the assets sit

Sep '26 · ₹ crore

Fixed assets (PPE)

₹326 cr13%

CWIP

₹358 cr14%

Investments

₹675 cr26%

Inventories

₹251 cr10%

Receivables

₹445 cr17%

Cash & equivalents

₹77 cr3%

Other assets

₹453 cr18%

Peer comparison

largest in Healthcare · this company in bold

Company	Market cap ₹cr	Price	P/E	P/B	ROE
Sun Pharmaceutical Industries Ltd.	4,46,270	1,860.00	40.7	5.00	12.3%
Divi's Laboratories Ltd.	2,73,493	10,320.50	93.5	16.32	17.5%
Torrent Pharmaceuticals Ltd.	1,80,671	4,750.00	85.1	9.83	11.6%
Laurus Labs Ltd.	1,26,430	2,340.00	94.4	20.86	22.1%
Apollo Hospitals Enterprise Ltd.	1,21,453	8,446.00	54.2	11.45	21.1%
Zydus Lifesciences Ltd.	1,19,550	1,197.90	28.6	4.30	15.0%
Dr. Reddy's Laboratories Ltd.	1,14,646	1,373.00	40.9	2.95	7.2%
Cipla Ltd.	1,13,988	1,411.00	39.3	3.22	8.2%
Mankind Pharma Ltd.	1,04,902	2,540.00	46.7	5.97	12.8%
Aurobindo Pharma Ltd.	1,03,572	1,800.00	26.0	2.63	10.1%
Blue Jet Healthcare Limited	10,482	553.80	36.7	4.56	12.4%

StoxGud checklist: Bullish setup · 8/10

Price above 50-day average
Price above 200-day average
50-day average above 200-day (uptrend)
RSI in healthy 40–70 zone
Positive 1-year return
Return on equity above 15%
Debt to equity below 1
Revenue growing year on year
Net profit margin above 10%
P/E below industry median

A rules-based screen of trend, momentum, quality and valuation. Educational only — not a buy or sell recommendation.

Returns & technicals

1 month+2.3%

6 months+12.9%

1 year-15.0%

3Y CAGR+13.1%

5Y CAGR—

10Y CAGR—

50-day avg₹544.58

200-day avg₹488.89

RSI (14)58

FAQs

What is the share price of Blue Jet Healthcare Limited?

Blue Jet Healthcare Limited (BLUEJET) closed at ₹553.80 on NSE on 06 Nov 2026.

What is the market cap of Blue Jet Healthcare Limited?

₹10,482 crore at the latest close.

What is the P/E ratio of Blue Jet Healthcare Limited?

36.7, on trailing-twelve-month earnings from its filings.

How fast is Blue Jet Healthcare Limited growing?

Blue Jet Healthcare Limited: Latest-quarter revenue is up 127.1% year on year, profit up 96.6%.

How profitable is Blue Jet Healthcare Limited?

On a trailing-twelve-month basis return on equity is 12.4%, return on capital employed 16.8%, operating margin 30.6%, net margin 26.0%.

How much debt does Blue Jet Healthcare Limited have?

Blue Jet Healthcare Limited is debt-free: debt to equity is 0.00 with borrowings of ₹0 cr against cash of ₹77 cr (balance sheet of 2026-09-30). Operating profit covers interest 174.1 times.

Financials parsed from Blue Jet Healthcare Limited's own XBRL filings to NSE (standalone), ₹ crore unless marked. Quarterly from SEP '23, annual from FY24, balance sheet from Sep '23. * = derived (full year or half year minus earlier quarters). Information only, not investment advice.